Literature DB >> 17872355

Management of patients with low-risk papillary thyroid carcinoma.

Ian D Hay1.   

Abstract

OBJECTIVE: To define a rational, cost-effective, simple approach to managing most patients with papillary thyroid cancer (PTC) who are at low-risk of either cause-specific mortality or tumor recurrence.
METHODS: Taking advantage of the collective experience of a cohort of 2512 patients with PTC who had initial definitive treatment at the Mayo Clinic in Rochester, Minnesota, between 1940 and 2000, a 5-step approach to the management of low-risk PTC has been devised. This program is based on appropriate preoperative ultrasound localization of neck disease and potentially curative surgery consisting of near-total or total thyroidectomy, with appropriate neck nodal exploration and resection.
RESULTS: The emphasis of the present program is on the extent of initial surgery, where optimal care is ascribed to a near-total thyroidectomy with curative intent and appropriate neck nodal resection as predicated by appropriate preoperative ultrasonography evaluation of regional lymph nodes. Radioiodine remnant ablation (RRA) is not applicable to patients with PTC who are defined on the day of definitive initial surgery to be at low risk as defined by a metastasis, age, completeness of resection, invasion, and size (MACIS) score of less than 6.
CONCLUSION: The outlook for patients with low-risk PTC is very optimistic, with rates at 30 postoperative years of only 1% for cause-specific mortality and less than 15% for tumor recurrence at any site. The long-term results obtained by potentially curative bilateral resection, appropriate regional lymph nodal excision, and selective use of RRA are excellent. Realistically improving these acceptably low rates for cause-specific mortality and tumor recurrence may be difficult.

Entities:  

Mesh:

Year:  2007        PMID: 17872355     DOI: 10.4158/EP.13.5.521

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  33 in total

1.  Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East versus West, whose policy is best?

Authors:  Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

2.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

3.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 4.  Observation for newly diagnosed micro-papillary thyroid cancer: is now the time?

Authors:  F Pacini
Journal:  J Endocrinol Invest       Date:  2014-10-26       Impact factor: 4.256

5.  Treatment decision making in early-stage papillary thyroid cancer.

Authors:  Thomas A D'Agostino; Elyse Shuk; Erin K Maloney; Rebecca Zeuren; R Michael Tuttle; Carma L Bylund
Journal:  Psychooncology       Date:  2017-02-27       Impact factor: 3.894

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015).

Authors:  Ian D Hay; Tammi R Johnson; Suneetha Kaggal; Megan S Reinalda; Nicole M Iniguez-Ariza; Clive S Grant; Siobhan T Pittock; Geoffrey B Thompson
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

8.  Dynamic contrast-enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers.

Authors:  Ramesh Paudyal; Yonggang Lu; Vaios Hatzoglou; Andre Moreira; Hilda E Stambuk; Jung Hun Oh; Kristen M Cunanan; David Aramburu Nunez; Yousef Mazaheri; Mithat Gonen; Alan Ho; James A Fagin; Richard J Wong; Ashok Shaha; R Michael Tuttle; Amita Shukla-Dave
Journal:  NMR Biomed       Date:  2019-11-04       Impact factor: 4.044

Review 9.  Prognostic utility of BRAF mutation in papillary thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

10.  The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study.

Authors:  Anna M Sawka; David P Goldstein; James D Brierley; Richard W Tsang; Lorne Rotstein; Shereen Ezzat; Sharon Straus; Susan R George; Susan Abbey; Gary Rodin; Mary Ann O'Brien; Amiram Gafni; Lehana Thabane; Jeannette Goguen; Asima Naeem; Lilian Magalhaes
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.